Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 3,908 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostatic Cancer Clear all
Active, not recruiting Phase 1 Interventional

Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer

NCT05479578
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) V8
Interventions
Cyclophosphamide, Dexamethasone
Drug
Lead sponsor
Rashmi Verma, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 21, 2026, 11:07 PM EDT
Completed Not applicable Interventional

Decision Support Interventions (DESI) for Prostate Cancer Screening and Treatment - Study 2

NCT01244568
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prostate cancer treatment DESI
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years and older · Male only
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Palo Alto, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 21, 2026, 11:07 PM EDT
Recruiting No phase listed Observational

Active Surveillance SNEP Assay Registry Trial for Prostate Cancer

NCT04052048
View directory record Official record
Conditions
Prostate Cancer Aggressiveness
Interventions
Subtraction Normalized Expression of Phagocytes Blood Test
Diagnostic Test
Lead sponsor
Immunis.AI
Industry
Eligibility
40 Years to 80 Years · Male only
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 21, 2026, 11:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Fish Oil and Green Tea Extract in Preventing Prostate Cancer in Patients Who Are at Risk for Developing Prostate Cancer

NCT00253643
View directory record Official record
Conditions
Precancerous Condition, Prostate Cancer
Interventions
green tea catechin extract, fish oil, placebo
Dietary Supplement · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
21 Years to 120 Years · Male only
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2013
U.S. locations
3
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 21, 2026, 11:07 PM EDT
Completed Phase 3 Interventional Results available

Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms

NCT02043678
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Matching placebo (normal saline), Abiraterone, Prednisone/Prednisolone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
29
States / cities
Anchorage, Alaska • Tucson, Arizona • Oceanside, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 21, 2026, 11:07 PM EDT
Completed Phase 1Phase 2 Interventional

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

NCT03543189
View directory record Official record
Conditions
Prostate Cancer, Prostate Disease
Interventions
Nivolumab, Brachytherapy, External Beam Radiation Therapy, Androgen Deprivation Therapy
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 21, 2026, 11:07 PM EDT
Recruiting Phase 2 Interventional

A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT07287150
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
Inavolisib, Enzalutamide, Abiraterone, Docetaxel
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 21, 2026, 11:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of a New Diagnostic Test on the Care of Prostate Cancer Patients: The ProMark™ Clinical Utility Study

NCT04550416
View directory record Official record
Conditions
Prostate Cancer
Interventions
ProMark Information and Test Results
Other
Lead sponsor
Qure Healthcare, LLC
Industry
Eligibility
Not listed
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Rafael, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 21, 2026, 11:07 PM EDT
Recruiting Early Phase 1 Interventional

A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

NCT05530655
View directory record Official record
Conditions
Prostate Cancer, Radiation Toxicity, Urinary Complication
Interventions
Lisinopril Tablets
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 21, 2026, 11:07 PM EDT
Completed Not applicable Interventional Results available

Diet and Physical Activity Intervention for the Prevention of ADT-Induced Metabolic Changes in Patients With Prostate Cancer, TRIPLE-A PILOT Study

NCT04870515
View directory record Official record
Conditions
Localized Prostate Carcinoma, Prostate Adenocarcinoma
Interventions
Best Practice, Dietary Intervention, Exercise Intervention, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
40 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 21, 2026, 11:07 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer

NCT02142608
View directory record Official record
Conditions
Prostate Cancer
Interventions
BR55
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
50 Years to 70 Years · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Oct 21, 2026, 11:07 PM EDT
Completed Early Phase 1 Interventional Results available

Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression

NCT03507608
View directory record Official record
Conditions
Prostate Cancer
Interventions
Flutamide, Placebo
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 21, 2026, 11:07 PM EDT
Completed Phase 2 Interventional Results available

Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7

NCT02601014
View directory record Official record
Conditions
Prostate Cancer, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma
Interventions
Ipilimumab, Nivolumab, Enzalutamide
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Oct 21, 2026, 11:07 PM EDT
Terminated Phase 2 Interventional

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

NCT05689021
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate/Niraparib, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Prednisone
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 21, 2026, 11:07 PM EDT
Terminated No phase listed Observational

UCI 03-72 Prostate Cancer Detection by Serum Proteomic Profiling

NCT00355758
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
University of California, Irvine
Other
Eligibility
50 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2010 · Synced Oct 21, 2026, 11:07 PM EDT
Recruiting Phase 2 Interventional

PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT

NCT07550517
View directory record Official record
Conditions
High-Risk Localized Prostate Cancer
Interventions
EBRT + 6 mo ADT + 177Lu-PSMA-617, EBRT + 24 mo ADT
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 21, 2026, 11:07 PM EDT
Recruiting Phase 2 Interventional

FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial

NCT06244004
View directory record Official record
Conditions
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Antiandrogen Therapy, Bone Scan, Computed Tomography, Cytotoxic Chemotherapy, FDG-Positron Emission Tomography, Radiation Therapy
Drug · Procedure · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Chicago, Illinois • DeKalb, Illinois • Geneva, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 21, 2026, 11:07 PM EDT
Completed Phase 4 Interventional

Local Anesthesia for Prostate Biopsy

NCT00422708
View directory record Official record
Conditions
Prostate Cancer
Interventions
Local anesthesia
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 20, 2010 · Synced Oct 21, 2026, 11:07 PM EDT
Completed Phase 2 Interventional Results available

Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking

NCT01535040
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Tobacco Use Disorder
Interventions
memantine hydrochloride, placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 21, 2026, 11:07 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer

NCT00939510
View directory record Official record
Conditions
Prostate Cancer
Interventions
sargramostim, lenalidomide, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
Robert Dreicer MD
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 21, 2026, 11:07 PM EDT
Completed Phase 2 Interventional Results available

An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer

NCT03338790
View directory record Official record
Conditions
Prostate Cancer
Interventions
nivolumab, docetaxel, enzalutamide, rucaparib, prednisone
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Male only
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
19
States / cities
Daphne, Alabama • Rancho Mirage, California • New Haven, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 21, 2026, 11:07 PM EDT
Not listed Phase 2 Interventional

MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer

NCT04876755
View directory record Official record
Conditions
Prostate Cancer Recurrent, Biochemical Recurrent Prostate Cancer
Interventions
MBM-02
Drug
Lead sponsor
Matrix Biomed, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Marina del Rey, California
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 21, 2026, 11:07 PM EDT
Recruiting Not applicable Interventional

Efficacy of Low-intensity Shockwave vs Radial Wave for Treatment of Erectile Dysfunction and Pelvic Pain

NCT05868668
View directory record Official record
Conditions
Erectile Dysfunction Due to Arterial Insufficiency, Erectile Dysfunction, Erectile Dysfunction Due to Arterial Disease, Chronic Pelvic Pain Syndrome, Chronic Prostatitis, Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction Following Radiation Therapy
Interventions
Focused shockwave, Radial wave, Sham treatment
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years and older · Male only
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 21, 2026, 11:07 PM EDT
Terminated Phase 1 Interventional

Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

NCT05999968
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Abemaciclib, Darolutamide, LHRH agonist/antagonist
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Springdale, Arkansas • Mineola, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 21, 2026, 11:07 PM EDT